顺铂/谷胱甘肽(Cisplatin/Glutathione) - 在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Glutathione/cisplatin、Glutoxim

+ [1]

靶点-

作用机制

DNA烷化剂

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症

乳腺癌白血病骨髓增生异常综合征+ [3]

原研机构

Cellectar Biosciences, Inc.

在研机构

Sleep Number Labs

非在研机构

Cellectar Biosciences, Inc.

最高研发阶段批准上市

首次获批日期

俄罗斯 (2001-07-03),

肿瘤

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式Cl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS号15663-27-1

查看全部结构式(2)

关联

5

项与顺铂/谷胱甘肽相关的临床试验

NCT00499122 / Completed临床2期IIT

Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer

RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving oxidized glutathione (NOV-002) together with doxorubicin and cyclophosphamide followed by docetaxel works in treating women with newly diagnosed stage II or stage III breast cancer.

开始日期2007-06-04

申办/合作机构

University of Miami

EUCTR2006-001990-32-IT / Not yet recruitingN/A

A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combination withPaclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for theTreatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) - ND

开始日期2006-11-22

申办/合作机构

Novelos Therapeutics, Inc.

NCT00347412 / Completed临床3期

Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC).
Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination with chemotherapy had a better response (their tumors got smaller in one United States Phase 1/2 trial) than patients who received chemotherapy alone; and in two Phase 2 trials done in Russian patients, at the end of one year, patients treated with NOV-002 with chemotherapy had a better survival rate than patients who did not receive NOV-002 with their chemotherapy.

开始日期2006-11-01

申办/合作机构

Cellectar Biosciences, Inc.

100 项与顺铂/谷胱甘肽相关的临床结果

登录后查看更多信息

100 项与顺铂/谷胱甘肽相关的转化医学

登录后查看更多信息

100 项与顺铂/谷胱甘肽相关的专利（医药）

登录后查看更多信息

59

项与顺铂/谷胱甘肽相关的文献（医药）

2022-06-01·Cell and Tissue Biology

Sigma-1 Receptor Ligands Chlorpromazine and Trifluoperazine Attenuate Ca2+ Responses in Rat Peritoneal Macrophages

Article

作者: Antonov, V G ; Milenina, L S ; Krutetskaya, Z I ; Krutetskaya, N I

Sigma-1 receptors are ubiquitous multifunctional ligand-regulated molecular chaperones in the endoplasmic reticulum membrane with a unique history, structure, and pharmacological profile. Sigma-1 receptors bind ligands of different chemical structure and pharmacological action and modulate a wide range of cellular processes in health and disease, including Ca²⁺ signaling. To elucidate the involvement of sigma-1 receptors in the processes of Ca²⁺ signaling in macrophages we studied the effect of sigma-1 receptor ligands, phenothiazine neuroleptics chlorpromazine and trifluoperazine, on Ca²⁺ responses induced by inhibitors of endoplasmic Ca²⁺-ATPases thapsigargin and cyclopiazonic acid, as well as by disulfide-containing immunomodulators Glutoxim and Molixan in rat peritoneal macrophages. Using Fura-2AM microfluorimetry we showed for the first time that chlorpromazine and trifluoperazine inhibit both phases of Ca²⁺ responses induced by Glutoxim, Molixan, thapsigargin, and cyclopiazonic acid in rat peritoneal macrophages. The data obtained indicate the participation of sigma-1 receptors in a complex signaling cascade caused by Glutoxim or Molixan and leading to an increase in intracellular Ca²⁺ concentration in macrophages. The results also indicate the involvement of sigma-1 receptors in the regulation of store-dependent Ca²⁺entry in macrophages.

2020-12-01·Bulletin of Experimental Biology and Medicine4区 · 医学

Human Diploid Fibroblast Cell Lines — a Model System for Studying Immunodulatory Properties of Modern Immunobiological Drugs and Viruses

4区 · 医学

Article

作者: Konyuschko, O I ; Kozhevnikova, T N ; Ishmuhametov, A A ; Ivanova, A L ; Ozherelkov, S V ; Sanin, A V ; Sotskova, S E ; Vorovich, M F

The immunomodulatory properties of immunobiological drugs Glutoxim and Phosprenyl we well as vesicular stomatitis virus and inactivated tick-borne encephalitis vaccine virus were studied using human diploid fibroblast cell line from the collection of M. P. Chumakov Federal Research Center for Research and Development of Immunobiological Products. All tested preparations exhibited immunomodulatory activity in human diploid fibroblast cell line. Glutoxim in doses of 0.1 and 0.25 μg/ml stimulated production of IL-6 and IL-10 during 24-48 h of culturing, but did not stimulate production of IL-1β. Phosprenyl, on the contrary, increased production of IL-1β and the levels of IL-6 and IL-10. Vesicular stomatitis virus stimulated the production of IL-1β, IL-6, and IL-10, while inactivated tick-borne encephalitis vaccine virus stimulated the production of cytokines IL-8 and IL-18. Immunomodulatory activity of inactivated tick-borne encephalitis vaccine virus was first demonstrated in the in vitro system.

2020-01-01·Doklady Biochemistry and Biophysics4区 · 生物学

Neuroleptic Chlorpromazine Modulates Ca2+ Responses in Macrophages

4区 · 生物学

Article

作者: Nozdrachev, A D ; Krutetskaya, Z I ; Milenina, L S ; Antonov, V G

Using Fura-2AM microfluorimetry, we have shown for the first time that sigma-1 receptor antagonist neuroleptic chlorpromazine significantly inhibits glutoxim- and molixan-induced Ca²⁺ responses and Ca²⁺ responses induced by endoplasmic reticulum Са²⁺-ATPase inhibitors thapsigargin and cyclopiazonic acid in rat peritoneal macrophages. The results suggest the involvement of sigma-1 receptors in the signaling cascade induced by glutoxim or molixan and leading to intracellular Ca²⁺ concentration increase and in the regulation of store-dependent Ca²⁺ entry in macrophages.

100 项与顺铂/谷胱甘肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XY	DB05393

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肿瘤	俄罗斯	Sleep Number Labs	2001-07-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非小细胞肺癌	临床1期	加拿大	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	意大利	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	美国	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	西班牙	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	乌克兰	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	俄罗斯	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	波兰	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	以色列	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床前	英国	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床前	瑞士	Cellectar Biosciences, Inc.	2006-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00345540 (CTgov)	临床2期	卵巢癌	15	Carboplatin+NOV-002	廠醖蓋鬱廠襯醖蓋鑰鑰(鹽選鬱醖獵積窪觸窪夢) = 夢膚顧簾淵齋襯簾夢網膚簾鹹顧憲淵積蓋積鏇 (鬱齋繭網鹽壓淵艱憲願, 鏇憲顧餘糧衊夢壓廠繭 ~ 齋鹹膚憲壓窪憲醖膚構) 更多	-	2015-03-10
WCLC2013	N/A	晚期肺非小细胞鳞癌一线	172	Cixutumumab 20 mg/kg + Pemetrexed 500 mg/m2 + Cisplatin 75 mg/m2	(簾獵窪夢繭遞鹽淵遞顧) = 壓夢繭網鹽簾醖衊獵憲選壓壓淵構構餘淵膚製 (鬱製積鏇廠膚鏇壓醖襯 ) 更多	不佳	2013-10-30
WCLC2013	N/A	晚期肺非小细胞鳞癌一线	172	Pemetrexed + Cisplatin	(簾獵窪夢繭遞鹽淵遞顧) = 夢憲鹹積鹹製顧積獵膚選壓壓淵構構餘淵膚製 (鬱製積鏇廠膚鏇壓醖襯 ) 更多	不佳	2013-10-30
NCT00499122 (CTgov)	临床2期	乳腺癌	41	CYCLOPHOSPHAMIDE+Doxorubicin+Docetaxel+NOV 002	願範憲觸蓋願網鑰艱構(衊遞糧鹽簾鬱夢廠衊觸) = 觸窪繭遞簾構製簾窪製膚膚蓋築網製鏇範簾蓋 (壓膚鬱簾膚繭夢膚網蓋, 築築膚鬱膚顧鏇獵鑰鹹 ~ 鑰淵夢廠壓鏇願餘糧遞) 更多	-	2013-03-29
NCT00499122 (Pubmed \| Breast Cancer Res)	临床2期	HER2 阴性乳腺癌新辅助	41	NOV-002	(範艱壓製範艱觸餘夢積) = 選艱鹽醖蓋膚築構鏇廠範築積淵鹽齋膚積積獵 (襯積積襯獵壓願範網範 )	-	2012-02-01
ASCO2010	临床3期	非小细胞肺癌	903	NOV-002 + paclitaxel + carboplatin	(鏇獵鹹製壓夢繭鬱鹹憲) = 網憲醖鹹鹹憲鹹醖鹹憲糧艱構築願鹽網膚夢鹽 (築網鏇構簾衊蓋鑰選淵 ) 更多	不佳	2010-06-20
ASCO2010	临床3期	非小细胞肺癌	903	paclitaxel + carboplatin	(鏇獵鹹製壓夢繭鬱鹹憲) = 糧遞淵築窪繭顧餘鏇夢糧艱構築願鹽網膚夢鹽 (築網鏇構簾衊蓋鑰選淵 ) 更多	不佳	2010-06-20
AACR2007	临床3期	肾脏毒性	-	Cisplatin + NOV-002	選積網製遞蓋構選壓廠(範遞鏇選獵鬱淵糧鹽淵) = 選遞膚鏇糧願蓋夢齋鏇鑰顧鹽築齋製鬱簾鹽選 (範淵鏇簾遞鹹艱築淵願 ) 更多	-	2007-05-01
ASCO2006	临床1/2期	非小细胞肺癌一线	44	NOV-002 + carboplatin and paclitaxel (i.m.)	(觸願築醖選網構壓醖鑰) = 範糧鏇鹹壓繭齋淵顧觸廠繭製壓衊淵簾製築廠 (鏇築顧壓遞醖鑰鹽鏇觸 ) 更多	积极	2006-06-20
ASCO2006	临床1/2期	非小细胞肺癌一线	44	NOV-002 + carboplatin and paclitaxel (s.c.)	(觸願築醖選網構壓醖鑰) = 鑰衊衊遞餘餘簾鏇鹹網廠繭製壓衊淵簾製築廠 (鏇築顧壓遞醖鑰鹽鏇觸 ) 更多	积极	2006-06-20